CYTH - Annovis Bio triggers Alzheimer's med-driven rally
Annovis Bio ([[ANVS]] +210.3%) has more than tripled in value in reaction to promising Phase 2 results for ANVS401, its lead asset for Alzheimer's disease ((AD)) and Parkinson's disease ((PD)).After 25 days of treatment, patients showed a statistically significant improvement of 4.4 points or 30% (p=0.04) in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11), a frequently used test in clinical trials for AD.Compared to the placebo group, those treated with ANVS401 achieved an improvement of 3.3 points or 22% (p= 0.13).However, the companies advancing treatments for Alzheimer's disease such as Cassava Sciences ([[SAVA]] +8.9%), Cyclo Therapeutics ([[CYTH]] +17.8%), have joined the rally even though Biogen ([[BIIB]] -0.8%) the developer of much anticipated Alzheimer's medicine aducanumab is trading lower.With a comparison to recent AD trials, Annovis Bio highlighted the strength of its data readout obtained from the double-blind, placebo-controlled study.In its EMERGE study, Biogen demonstrated an improvement of 1.4-points in ADAS-Cog13 in 2019 over one year for its Alzheimer's asset aducanumab.In
For further details see:
Annovis Bio triggers Alzheimer's med-driven rally